This study, based on epidemiological evidence of serum IGF-I levels and prostate cancer risk among different populations worldwide, combined with the latest large-sample, multicenter original studies and genetic epidemiological results, explores the application value of IGF-I as a potential biomarker in early screening and risk stratification of prostate cancer. The gene discussed is IGF1; the disease is prostate cancer.